Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response
Xiaochun Liu, Patricia Lorusso, Monica Mita, Sarina Piha-Paul, David S Hong, Siqing Fu, Lacey McQuinn, Ekaterine Asatiani, Lawrence A Doyle, Helen X Chen, Kenneth R Hess, Razelle Kurzrock, Aung Naing, Xiaochun Liu, Patricia Lorusso, Monica Mita, Sarina Piha-Paul, David S Hong, Siqing Fu, Lacey McQuinn, Ekaterine Asatiani, Lawrence A Doyle, Helen X Chen, Kenneth R Hess, Razelle Kurzrock, Aung Naing
Abstract
Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor-based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enable patients to continue effective treatment while maintaining good quality of life.
Trial registration: ClinicalTrials.gov NCT00678769 NCT01378377 NCT01529593.
Source: PubMed